BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
HYRIMOZ (adalimumab-adaz) by Novartis is tumor necrosis factor receptor blocking activity [moa]. Approved for rheumatoid arthritis, crohn's disease, psoriasis and 4 more indications. First approved in 2018.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (7)
Worked on HYRIMOZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.